1L

Rs115.95

Rs112.00

-3.4%


0.0%

-3.4%

Rs300.642M

US\$7,376M





Company Flash

25 April 2007 | 6 pages

IDEA Cellular (IDEA.BO)

Buy: 4QFY07 - Wireless Growth Accentuated by Other Income

- Results in-line Idea Cellular's 4QFY07 EBITDA at Rs4,360m was in-line with expectations on the back of strong revenue growth and modest margin gains. Net profit at Rs1,934m was, however, significantly ahead of expectations due to high other income and lower-than-expected depreciation.
- Wireless growth on track Wireless revenue growth at 14.1% qoq (est.) was robust, higher than in the immediate past. EBITDA margins at 33.3% improved by 30bps qoq, after adjusting for certain flexible-pay provisions that inflated staff costs in 3QFY07. Management indicated EBITDA margins in 8-old circles at 38.7%.
- KPIs under control despite new rollouts— ARPUs declined only 2% gog as the new launches did not have an adverse impact, implying rational pricing. The decline in rev/min was also moderate (Rs0.87 to Rs0.82), mainly on account of roaming tariff cuts.
- Captive NLD profitability, a small surprise NLD revenues of Rs603m with an EBIT of Rs126 was a small surprise, but mainly on account of captive traffic being carried on leased lines. At this stage, therefore, it is more a tool to save costs rather than a full-fledged business model. Management indicated they will take a final decision on NLD business model by 1QFY08.
- Surplus cash led to high other income 4QFY07 other income at Rs.326.4m was higher than expected on account of treasury gains due to the surplus cash on from the IPO, and would trend down as it gets deployed in the rollout.

Buy/Low Risk

Target price

Market Cap

Price (25 Apr 07)

Expected share price return

Expected dividend yield

Expected total return

Figure 1. Statistical abstract

	EBITDA	Net Profit	FD EPS	EPS Growth	P/E	EV/EBITDA	Price/CEPS
	(Rs m)	(Rs m)	(Rs)	(%)	(x)	(x)	(x)
2005P	8,210	760	0.1	na	na	na	na
2006P	10,674	2,118	0.7	na	na	na	na
2007E	14,635	4,229	1.6	119%	72.0	22.7	27.5
2008E	21,873	6,631	2.5	54%	46.7	16.0	17.7
2009E	29,762	9,379	3.6	41%	33.0	12.1	13.1

Source: Citigroup Investment Research

Rahul Singh¹

+91-22-6631-9863 rahul.r.singh@citigroup.com

Gaurav Malhotra¹

gaurav.a.malhotra@citigroup.com

Anand Ramachandran, CFA²

+852-2501-2448

anand.ramachandran@citigroup.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE

¹Citigroup Global Market India Private Limited; ²Citigroup Global Markets Asia

http://deadpresident.blogspot.com

Figure 2. Financial statement

Rs.m	Jun-06	Sep-06	Dec-06 (est.)	Mar-07	FY07
Service Revenue	8,939.9	10,013.0	11,463.3	13,084.2	43,664.0
qoq growth (%)	9.4	12.0	14.5	14.1	NA
Sales of Trading Goods	62.4	83.0	18.4	-	-
Total Income	9,002.2	10,096.0	11,481.6	13,084.2	43,664.0
Cost of Trading Goods	(20.0)	(28.0)	(13.4)	0	(51.7)
Personnel Expenditure	(554.0)	(600.0)	(759.0)	(684.7)	(2,597.7)
Network Operating Exp	(1,045.0)	(1,144.0)	(1,410.2)	(1,680.0)	(5,279.2)
License & WPC Charges	(909.0)	(995.0)	(1,172.1)	(1,410.9)	(4,487.0)
Access & Interconnect Charges	(1,513.0)	(1,622.0)	(1,949.6)	(2,202.5)	(7,287.1)
Subscriber Acquisition & Servicing & Advertisement & Business Promotion Exp	(1,536.0)	(1,736.0)	(1,985.5)	(2,179.2)	(7,437.7)
Administration & Other Exp	(395.0)	(432.0)	(486.5)	(564.0)	(1,887.1)
Total Opex	(5,972.0)	(6,557.0)	(7,777.2)	(8,721.3)	(29,027.5)
Impact of Restatement	4.0	(3.0)	0	0	0
Restated Total Opex	(5,976.0)	(6,554.0)	(7,777.2)	(8,721.3)	(29,027.5)
EBITDA	3,026.2	3,542.0	3,704.4	4,362.9	14,636.5
Margin %	33.6%	35.1%	32.3%	33.3%	33.5%
Depreciation & Amortisation	(1,456.4)	(1,700.0)	(1,800.5)	(1,761.3)	(6,718.2)
EBIT	1,569.9	1,842.0	1,903.9	2,601.60	7,918.30
Interest & Financing Charges	(737.1)	(774.0)	(805.4)	(974.7)	(3,291.2)
Other Income	19	11	108.9	326.4	465.3
PBT	851.8	1,079.0	1,207.4	1,953.3	5,092.4
Tax	(4.0)	(6.0)	(30.7)	(19.1)	(59.8)
PAT	847.7	1,073.0	1,176.7	1,934.2	5,032.6
PAT Margin %	9.4	10.6	10.2	14.8	11.5
Source: Citigroup Investment Research, Com	pany reports				

Figure	3.	Qua	rterlv	KPIs
6	••	~~~	,	

	Mar-06	Jun-06	Sep-06	Dec-06	Mar-07
ARPU	381	362	335	322	317
MOU	302	342	344	369	387
Revenue per min	1.26	1.06	0.98	0.87	0.82
Subscribers ('000)	7,366	8,535	10,362	12,442	14,010
Pre-paid as % of total	82%	84%	86%	88%	89%
Total MOU (mn min)	7,008	8,097	9,736	12,629	15,469
Post-paid churn %	5.5%	4.7%	4.8%	4.4%	4.2%
Pre-paid churn %	6.3%	5.3%	4.3%	3.6%	4.2%

Unexpectedly high other income and lower depreciation charges aid the bottom line

Figure	Λ	Operating	reculte	in line	with	expectations
rigure	4.	Operating	resums	m-me	willi	expectations

Rs.m	Estimates	Actual	% difference
Sales	12,800	13,084	2.2
EBITDA	4,362	4,363	0.0
PAT	1,131	1,934	71.0

Source: Citigroup Investment Research, Company reports

http://deadpresident.blogspot.com

IDEA Cellular

Company description

Idea Cellular, a pure play wireless provider, is the fifth-largest cellular operator in India. It has licenses to provide cellular-phone services in 13 of the 23-telecom circles in India and has an active presence in 11 of them. The company listed on the Indian bourses in March 2007 and is part of the Aditya Birla Group.

Investment thesis

We rate Idea as Buy/Low Risk. Continued robust wireless market expansion and Idea's ability to regain its growth potential post its restructuring and full control by Aditya Birla Group are the key factors to our investment argument. The company's IPO provided sufficient funding flexibility to pursue its growth plans. Idea's strong competitive position and comparable operational parameters provide us sufficient comfort in management's ability to execute its plans. Given the spectrum issues facing potential new entrants, Idea should remain relatively unconstrained for the next 12-18 months. As a result, we estimate an earnings CAGR of 47.7% over FY07-09E, well ahead of its peers and more than double that of the broader market. From an industry perspective, we believe that low revenue yields and moderate EBITDA margins leave little room for disruptive pricing. Additionally, most regulatory concerns are now addressed and potentially costly 3G auctions cannot derail it from its growth path, in our view

Valuation

We have set our 12-month target price at Rs112 based on Mar-08E DCF, which we think is an appropriate method due to the back-ended nature of free cash flows given the new circle roll-outs. Our DCF assumes a WACC of 10.8% at a target debt to capital of 50.0% and terminal growth rate of 4.0% (similar to Bharti). Our DCF is based on explicit forecasts for FY07-16E with a terminal year EBITDA margin at 37.1% (~200bps below Bharti) and capex/sales of ~10% (in line with Bharti). The target price imlies an EV/EBITDA of 11.6x, a slight premium to Bharti's target multiples (for the ex-towerco portion of Rs800), which we believe is supported by (1) higher EBITDA growth rates for Idea; (2) liquidity overflow from Bharti's foreign limit constraints; and (3) M&A possibilities in the long run given Idea's good fit for the potential suitors.

Risks

Our quantitative risk rating system assigns a default Speculative Risk rating to Idea due its trading history of less than 12 months. We believe, however, that a Low Risk rating is more appropriate due to the higher visibility of Indian wireless growth, Idea's reasonably competitive position, strong parentage and the reduction of financial leverage post-IPO. Operationally, the risks facing Idea are slightly higher than its more established peers on account of the roll out in new circles. Project cost over-runs, delays in spectrum allocation and hence commercial launches could affect the value accretion opportunity in the new circles. Idea will also face competition from the established players in the new circles and market share gains may be lower than expected. Idea will incur higher capex requirements in the new circles due to the coverage compulsions, which may depress return parameters in the initial years. Any rollout plans beyond 13 circles may also require a fresh equity infusion. These risk factors could impede the stock from reaching our target price.

http://deadpresident.blogspot.com

Appendix A-1

Analyst Certification

We, Rahul Singh and Anand Ramachandran, CFA, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

IDEA Cellular (IDEA.BO) Ratings and Target Price History - Fundamental Research Target Closina Analyst: Rahul Singh (covered since April 12 2007) Price 1: 12 Apr 07 1L 112.00 98.15 Indicates change as of 21 200 M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A Covered Not covered

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of IDEA Cellular. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of IDEA Cellular.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from IDEA Cellular.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from IDEA Cellular in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): IDEA Cellular.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: IDEA Cellular.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: IDEA Cellular.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 31 March 2007	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3215)	45%	40%	15%
% of companies in each rating category that are investment banking clients	45%	42%	32%
India Asia Pacific (130)	58%	14%	28%
% of companies in each rating category that are investment banking clients	42%	50%	42%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 15%-30% for High-Risk sto

25 April 2007

http://deadpresident.blogspot.com 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citigroup Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L). Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings.

CBR risk ratings are approximately equivalent to the following matrix:

Low Risk -- Triple A to Low Double A Low to Medium Risk -- High Single A through High Triple B Medium to High Risk -- Mid Triple B through High Double B High to Speculative Risk -- Mid Double B and Below

The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed-income security issued by a company is held to maturity. based upon both fundamental and market risk factors. Certain reports published by Citigroup Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citigroup Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight -- the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market). performances of which are updated monthly and can be viewed at http://www.sd.nv.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight -- the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight -- the bond is expected to underperform the relevant sector of the Citigroup indexes.

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 25 April 2007 01:11 PM on the issuer's primary market.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of equity securities of IDEA Cellular.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of IDEA Cellular.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of IDEA Cellular.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

http://deadpresidentiblogspot.com The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made

available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong, Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change, If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST